New drug duo takes on stubborn Epstein-Barr virus

NCT ID NCT07369739

Recruiting now Disease control Sponsor: Beijing Friendship Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether combining two drugs, golidocitinib and selinexor, can control chronic active Epstein-Barr virus disease (CAEBVD). Researchers will enroll 28 adults with CAEBVD and track how well the treatment reduces symptoms and lowers virus levels in the blood. It is an early-phase trial without a placebo group, so results will show if the approach is promising enough for larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: golidocitinib and selinexor (combination drug therapy)
What this could lead to: If it works, this could offer a new treatment option to control chronic active Epstein-Barr virus disease and reduce virus levels in the blood.
What could go wrong: This is an early-phase trial with only 28 participants and no comparison group, so results may not apply broadly. The drugs may cause side effects or fail to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CAEBV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Epstein-Barr virus infection hemophagocytic syndrome immunodeficiency 32B

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CAEBV EBV LYMPHOHISTIOCYTOSIS

Contacts and locations

Locations

Beijing Friendship Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.